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There is overwhelming evidence that statins reduce morbidity and mortality in patients with coronary disease.
Statins have also been shown to reduce the risk of (recurrent) stroke. Low-density lipoprotein (LDL)-cholesterol,
which plays a causal role in the development of atherosclerotic disease, is the primary lipid target in prevention, and
is effectively reduced by these agents. In this review, studies are summarized addressing the issues whether statins
also directly influence the atherosclerotic process in peripheral arterial disease, carotid artery stenosis, and growth of
abdominal aortic aneurysms, and whether statins have an effect on perioperative outcomes in vascular surgery
patients. It appears that the evidence of statins on peripheral arterial disease is scarce and its effect on perioperative
outcome inconclusive. Prospective randomized trials to answer these questions cannot be performed anymore,
however, because all vascular patients should receive statin treatment as secondary prevention of cardiovascular
disease. ( J Vasc Surg 2009;49:260-5.)HMG-CoA reductase inhibitors (or statins) effectively
decrease serum cholesterol and there is ample evidence that
cholesterol lowering with statins reduce morbidity and
mortality in cardiovascular patients. The first large placebo-
controlled trial was the 4S trial with simvastatin, which
revolutionized clinical practice of cardiologists.1 This was
followed by many other large trials in several categories of
high-risk patients (diabetes, hypertension, elderly, or acute
coronary syndrome) and comparisons with conventional
and more intensive cholesterol-lowering therapy, which all
gave a similar picture and indicated, in addition, that fur-
ther lowering of serum cholesterol was associated with even
more risk reduction. The largest of these trials is the Heart
Protection Study (HPS), in which a large number of pa-
tients with peripheral vascular disease were also included.2
Based on placebo-controlled studies containing more than
90,000 patients, it has been shown that there is a strong
proportional relationship between the degree of low-density
lipoprotein (LDL)-cholesterol lowering and reduction in car-
diovascular events.3,4 There have been a few exceptions in this
series of successful trials with neutral outcome: diabetic pa-
tientswith endstage renal disease ondialysis5 andpatientswith
heart failure,6 in whom vascular damage is apparently irrevers-
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260ible, or vascular disease so complex that treatment with statins
is ineffective or has come too late.
The etiology of atherosclerotic vascular disease in the
various parts of the arterial tree resulting in myocardial
infarction, ischemic stroke, and peripheral disease is es-
sentially the same. In addition, a considerable number of
vascular patients present with manifestations of athero-
sclerosis in several parts of the arterial tree at the same
time.7 Several intervention trials have indicated that
statins not only prevent cardiac events in cardiovascular
patients, but also ischemic stroke and peripheral arterial
disease.2,8 There is only one randomized trial in patients
with a stroke or transient ischemic attack (TIA) without
manifest coronary disease, aimed to specifically study the
effect on recurrent stroke;9 this study using a high dose
of 80 mg atorvastatin, showed a 16% reduction in fatal
and non-fatal stroke and 26% reduction in total vascular
events.
The purpose of this evidence-based review series is to
look at the evidence that statins are also beneficial in
preventing progression of atherosclerotic disease in other
areas than the coronaries, ie, carotid arteries, abdominal
aortic aneurysm, and peripheral arterial disease. Evidence
that statins have direct beneficial effects on these parts of
the arterial tree resulting in less clinical endpoints is scarce
and difficult to obtain since all vascular patients are re-
garded as having high-risk and usually already treated with
statins according to the current guidelines.
METHODS
From a literature search in PubMed, studies were se-
lected evaluating the effect of treatment with statins on
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was confined to three main vascular areas, carotid arteries,
abdominal aorta, and peripheral (infrainguinal) arteries.
Both effects on clinical outcome in terms of progres-
sion of disease as well as on perioperative outcome have
been reported.
Most strikingly, the majority of these studies are observa-
tional and retrospective in nature, of limited duration, usually
Table I. Clinical trials in patients with carotid artery steno
Study Study design
Population/
procedure
Numb
(statin u
Kennedy et al19 Observational,
retrospective
CEA n  3360
Asymptomat
Symptomati
McGirt et al20 Observational,
retrospective
CEA n  1566
(42% sympto
(657/909)
Brooke et al21 Case control,
retrospective
CEA n  1561
660 symptom
901 asympto
OR, Odds ratio; HR, hazard ratio; CI, confidence interval; CEA, carotid en
*OR (and HR, or relative risk ratio): ratio of the odds (OR) or probability (H
or probability (HR) of it occurring in the control group. An OR or HR ra
OR/HR less than 1 indicates that the event is less likely in the first group.
Table II. Clinical trials in patients with AAA
Study Study design
Population/
procedure
Number o
(statin user
Kertai et al22 Observational,
retrospective
AAA elective
surgical repair
n  510 (
Sukhija et al23 Observational,
prospective
AAA
surveillance
n  130 (
Schouten et al24 Observational,
retrospective
AAA
surveillance
n  150 (
Mosorin et al25 Observational,
retrospective
AAA
surveillance
n  121 (
Schlösser et al26 Observational,
prospective
Small AAA
(30-55 mm)
surveillance
n  230 (
AAA, Abdominal aortic aneurysm; OR, odds ratio; HR, hazard ratio; CI, c
*OR (and HR, or relative risk ratio): ratio of the odds (OR) or probability (H
or probability (HR) of it occurring in the control group. An OR or HR ra
OR/HR less than 1 indicates that the event is less likely in the first group.conducted in complex patients withmultiple pharmacologicaltreatments without information about type of statin, dosing,
exact duration of treatment, compliance, and levels of LDL-
and high-density lipoproteins (HDL)-cholesterol. Many pos-
sible confounders are not controlled for and causal relation-
ships are therefore not proven. There are a few exceptions.
RESULTS
Carotid artery stenosis (Table I). Paraskevas et al10
ndergoing carotid endarterectomy (CEA)
atients
on users) OR or HR and (95% CI) vs non statin users*
5/587)
5/1216)
In-hospital adverse outcome (death/stroke/
cardiac events)
Asymptomatic: no difference
Symptomatic: death: OR 0.25 (0.07-0.90)
Stroke: OR 0.55 (0.32-0.95)
Cardiac events: no difference
c)
Perioperative outcome (mortality, stroke,
myocardial infarction, cranial nerve injury,
length of hospital stay)
Death: OR 0.20 (0.04-0.99)
Stroke: OR 0.35 (0.15-0.85)
(228/432)
c (426/475)
Presence of symptomatic cerebrovascular disease
at time of presentation for CEA
OR 0.72 (0.56-0.92)
rectomy.
f an event occurring in the therapeutic group as compared to the odds (OR)
ater than 1 indicates that the event is more likely in the first group and an
ients
users) OR or HR and (95% CI) vs non statin users*
356) All cause mortality and cardiovascular mortality
Median follow-up 4.7 years
All cause mortality HR 0.6 (0.5-0.9), cardiovascular
mortality HR 0.7 (0.4-0.9)
5) AAA growth rate
Follow-up 2 years
No change in statin users, increase from 45 to 53 mm
in nonusers
1) AAA growth rate
Follow-up 3.1 years
1.16 mm/year (0.33 to 1.99 mm) less growth in statin
users compared with nonusers
7) AAA growth rate, survival from repair/rupture
Mean follow-up 3.6 years
Growth rate NS
Survival at 5 years in statin users 84% vs 59% in nonusers
45) Mortality, rupture rates, AAA growth rate
Median follow-up 3.3 years
7 ruptures (6 fatal)
Mortality NS
1.2 mm/year (2.34-0.060 mm/year) less growth in
statin users compared with nonusers
nce interval; NS, not significant.
f an event occurring in the therapeutic group as compared to the odds (OR)
ater than 1 indicates that the event is more likely in the first group and ansis u
er of p
sers/n
ic (66
c (81
mati
atic
mati
darte
R) of pat
s/non
154/
75/5
59/9
34/8
85/1
onfide
R) o
tio grehave published an extensive review article in this journal
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ness (IMT) and occurrence of cerebrovascular disease.
There is evidence that the progression rate of IMT is
Table III. Clinical trials in patients with PAD
Study Study design
Population/
procedure
McDermott et al27 Observational,
retrospective cross
sectional
ABI 0.90 vs ABI
0.90-1.50
Mohler et al28 Randomized,
double blind,
parallel design,
placebo, 10 mg
and 80 mg
atorvastatin
Intermittent
claudication
Mondillo et al29 Randomized,
placebo
controlled,
double blind 40
mg simvastatin vs
placebo
Intermittent
claudication,
Cholesterol 5.69
mmol/L
Schillinger et al30 Observational,
prospective
Severe PAD,
percutaneous
catheter
intervention
Henke et al31 Observational,
retrospective
PAD infrainguinal
bypass
Abbruzzese et al32 Observational,
retrospective
PAD infrainguinal
bypass
Ward et al33 Observational,
retrospective
PAD infrainguinal
bypass
Feringa et al11 Observational,
prospective
PAD (ABI 0.90)
Schanzer et al12 Observational,
analysis of
PREVENT III
Cohort
PAD infrainguinal
bypass
OR, Odds ratio; HR, hazard ratio; CI, confidence interval; PAD, periphera
ABI, ankle brachial index.
*OR (and HR, or relative risk ratio): ratio of the odds (OR) or probability (H
or probability (HR) of it occurring in the control group. An OR or HR ra
OR/HR less than 1 indicates that the event is less likely in the first group.reduced by statins, but controlled studies specifically oneffect on carotid plaques are lacking. Perioperative out-
come in symptomatic patients undergoing endarterectomy
may be better in statin users but the level of evidence is not
umber of patients
tin users/non users)
OR or HR and (95% CI) vs non statin
users*
92 (177/215)
49 (75/174)
Better walking performance in statin users
54
bo 114
g 120
g 120
Change in treadmill exercise, patient-
reported physical activity and quality of
life questionnaire
Follow-up 1 year
No difference in maximal walking time,
pain-free walking time improved in 80
mg group
6 (43/43) Treadmill test, ABI at 3 and 6 months
follow-up
More increase in pain-free walking
distance (90 m) and total walking
distance (116 m) and small increase in
ABI in the simvastatin group.
15 (269/246) All cause mortality, composite of
myocardial infarction and death
Median follow-up 21 months
Mortality: HR 0.52 (0.30-0.91)
Myocardial infarction and death; HR
0.48 (0.29-0.79)
93 (164/129) Graft patency, limb salvage, mortality
Mean follow-up 17 months.
Graft patency: OR 3.7 (2.1-6.4)
Amputation rate: OR 0.34 (6.15-0.77)
Mortality: NS
72 (189 procedures)
/95)
Graft patency, limb salvage, mortality
Mean follow-up 17.5 months.
Patency rates: NS
Limb salvage: NS
Mortality: NS
46 (72/374) Perioperative complications (all cause
mortality, cardiovascular mortality,
myocardial infarction, stroke, major
peripheral vascular complications);
long-term survival
Mean follow-up 5.5 years.
Combined complications: OR 0.36
(0.14-0.93)
Long-term survival: OR 0.52 (0.32-0.84)
374 (481/893) All cause mortality, cardiac death,
progression to kidney failure
Mean follow-up 6.4 years
Per 10% increase in statin dose and 10
mg/dl lower LDL-cholesterol:
mortality: HR 0.71 (0.62-0.80)
cardiac death: HR 0.76 (0.67 -0.82)
kidney failure: HR 0.69 (0.54-0.89)
401 (636/768) 30-day MACE, death, 1-year graft
patency and mortality
30-day: MACE and death: NS
1 year graft patency: NS
1 year mortality: HR 0.71 (0.52-0.98)
y disease; NS, not significant; MACE, major adverse cardiovascular events;
f an event occurring in the therapeutic group as compared to the odds (OR)
ater than 1 indicates that the event is more likely in the first group and anN
(sta
n  3
n  2
n  3
place
10 m
80 m
n  8
n  5
n  2
n  1
(94
n  4
n  1
n  1
l arterstrong.
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number of subjects with AAA in the various studies is rather
small and the studies are all observational in nature. In
general, the growth rate of AAAmay be reduced in patients
using statins and mortality less, but the number of studies
and evidence are limited.
Peripheral artery disease (PAD) (Table III). The
studies looking at the clinical effect of statins in patients
with claudication or after infrainguinal bypass surgery are
all observational and provide a variable picture, but the
majority reports a beneficial effect on walking performance,
patency, and survival in the statin users. The two largest
studies showed improved survival: Feringa et al11 compared
481 statin users with 893 non users with ankle brachial
index (ABI) 0.90 during a mean follow-up of 6.4 years
and found reduced mortality, cardiac death, and kidney
failure per 10% increase in statin dose and 10 mg/dL lower
LDL-cholesterol. Schanzer et al12 made use of the Project
of Ex-vivo vein graft Engineering via Transfection III
(PREVENT III) cohort of 1404 patients undergoing lower
extremity bypass grafting (testing the efficacy of edifoligide
Table IV. Clinical trials in patients with peripheral vascula
Study Study design Population/p
Poldermans et al14 Case controlled,
retrospective
Major vascular
(non-cardiac)
O’Neil-Callahan et al13 Observational,
retrospective
CEA, aortic sur
lower limb
revascularizat
Heart Protection
Study (HPS)
Collaborative Group16
Randomized, placebo
controlled double
blind (40 mg
simvastatin/placebo
Claudication,
revascularizat
amputation,
repair (Subgr
HPS)
Van Gestel et al15 Observational,
retrospective
Elective surgery
CEA, lower l
arterial recon
with and with
COPD
OR,Odds ratio;HR, hazard ratio; CI, confidence interval; CEA, carotid en
NS, not significant; MACE, major adverse cardiovascular events; COPD, ch
*OR (and HR, or relative risk ratio): ratio of the odds (OR) or probability (H
or probability (HR) of it occurring in the control group. An OR or HR ra
OR/HR less than 1 indicates that the event is less likely in the first group.to reduce neointimal hyperplasia, which did not conferbenefit). This study (636 statin users vs 768 non users)
revealed no effect on patency, but improved survival 1 year
after surgical revascularization.
Combined peripheral vascular disease (carotid ar-
tery, aorta, and lower extremity) (Table IV). Earlier
retrospective studies investigated the perioperative mortality
and in-hospital complications of major vascular surgery and
found less complications in statin users, whereas myocardial
infarction/death were not significantly different;13 Polder-
mans et al14 reported in a retrospective case-controlled
study reduced perioperative mortality. The same group
reported improved short- and long-term survival in patients
with PAD and chronic obstructive pulmonary disease on
intensified doses of statins.15
The best evidence comes from the Heart Protection
Study.2,16 In this randomized, placebo controlled, double
blind study, a subgroup of 6748 patients with PAD were
included and allocated to either 40 mg of simvastatin or
placebo during a mean of 5 years. There was a significant
22% relative reduction in the rate of first major vascular
events. Overall, there was a significant 16% reduction in the
ease (combined carotid, aorta and lower extremity)
re
Number of patients
(statin users/non users)
OR or HR and (95% CI) vs
non statin users*
ry n  2816
160 cases, 320 controls
(12/160; 81/320)
Perioperative mortality
OR 0.22 (0.10-0.47)
n  997, (1163
hospitalizations)
(526/637)
Total in-hospital complications
(death, myocardial
infarction, myocardial
ischemia, congestive heart
failure, ventricular
tachyarrhythmia)
Complications: OR 0.56
(0.39-0.79)
Myocardial infarction/death:
NS
ysm
n
n  6748 (3384/3364) MACE, coronary event, stroke,
revascularization, first PAD
events Mean follow-up 5
years.
MACE: HR 0.76 (0.72-0.81)
Coronary events: HR: 0.73
(0.67-0.79)
Stroke: HR 0.75 (0.66-0.85)
Revascularization: HR 0.76
(0.70-0.83)
First PAD events: 16% (5-25)
relative reduction
AA,
tion
n  3371 (810/2561) 30-day and 10-year mortality
30-day: OR 0.45 (0.27-0.75)
10 year: HR 0.72 (0.60-0.85)
COPD: 30-day: OR: 0.48
(0.23-1.00)
10-year: HR 0.67 (0.52-0.86)
ctomy;HPS, hyperperfusion syndrome; AAA, abdominal aortic aneurysm;
obstructive pulmonary disease.
f an event occurring in the therapeutic group as compared to the odds (OR)
ater than 1 indicates that the event is more likely in the first group and anr dis
rocedu
surge
gery,
ion
ion,
aneur
oup i
for A
imb
struc
out
dartere
ronic
R) orate of first peripheral vascular events. Around 2700 pa-
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at baseline and achieved similar proportional benefits as
those with coronary artery disease and PAD.16
DISCUSSION
This review summarizes the evidence for the beneficial
effects of statins in non-cardiac vascular surgery patients
with respect to clinical symptoms and/or perioperative
outcome. Since patients with symptomatic PAD have fre-
quently co-existing coronary disease and a high risk to
develop cardiovascular events, they should be treated with
statins according to current guidelines. This will make
future randomized controlled studies impossible to con-
duct. The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial, with high dose of ator-
vastatin, has shown to reduce the risk of recurrent fatal and
non-fatal strokes in patients with a history of ischemic
stroke or TIA, but without manifest coronary disease (sec-
ondary prevention). A difference in LDL-cholesterol of 1.4
mmol/L was associated with a significant absolute 5-year
risk reduction of fatal and non-fatal stroke of 2.2%, whereas
the risk of major cardiovascular events was reduced by
3.5%.9 It was already known that stroke or TIA should be
regarded as “coronary heart disease risk equivalent” for
which secondary more aggressive prevention guidelines
apply. The studies summarized in this review also suggest
beneficial effect on the progression of PAD, but hard
clinical evidence for these peripheral beds is scarce due to
the non-randomized nature of most studies with many
possible confounders and comes mainly from the hyperper-
fusion syndrome (HPS). Furthermore, although some
studies suggest benefit with respect to perioperative com-
plications, mortality, and clinical outcome, the protective
effect of statins are not proven in these situations. Biccard17
provides useful recommendations for perioperative statin
use, so that meta-analysis in the future may provide an
answer whether statins will reduce perioperative complica-
tions. The same holds true for the effect of statins on the
progression rate of AAAs: there is no conclusive evidence
that these drugs prevent growth and ruptures of AAA.
It has been suggested that the statins exert their effect as
anti-inflammatory agents independent of their cholesterol
lowering effect. Statins are indeed known to lower high
sensitive C-reactive protein (hs-CRP).18 It remains to be
seen, however, whether these effects are really cholesterol-
independent, because the clinical effects of statins are pro-
portionally (one-to-one) related to the degree of LDL-
cholesterol lowering.3,4 The clinical relevance of this so
called pleiotropic effect has not been proven so far. In conclu-
sion, life style measures, smoking cessation, and cholesterol
lowering remain of utmost importance to influence favor-
ably (cardiovascular) outcome in vascular patients. Despite
the relative shortcomings in direct clinical evidence for the
beneficial effect of statins in particular parts of the vascular
tree, statins have become, beyond a doubt, an essential
instrument in the management of the vascular patient.AUTHOR CONTRIBUTIONS
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